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survival (bPFS), cause-specific survival (CSS), and overall survival (OS) in Gleason 7 prostate
cancer patients treated with low-dose-rate (LDR) interstitial brachytherapy with or without supple-
mental external beam radiation therapy and androgen deprivation therapy.
METHODS AND MATERIALS: We retrospectively reviewed the medical records of 932
consecutive patients with biopsy-confirmed Gleason 7 prostate cancer who received LDR interstitial
brachytherapy as a component of their definitive treatment regimen. Treatment outcomes were
compared between patients with primary Gleason pattern 3 and 4.
RESULTS: With a median followup of 7.4 years, the 10- and 14-year bPFS, CSS, and OS for the
entire Gleason 7 study group were 95.7/95.7%, 98.6/98.6% and 77.2/64.3%, respectively. When
biochemical control was evaluated as a function of primary Gleason pattern, the primary pattern
3 had a statistically higher 10- and 14-year bPFS (97.8/97.8% vs. 93.1/93.1%, p5 0.006). The
Gleason pattern 3 patients also trended toward a higher 10- and 14-year CSS (99.3/99.3% vs.
96.9/96.9%, p5 0.058). OS was not statistically different between the two Gleason 7 cohorts.
CONCLUSIONS: Gleason 7 prostate cancer patients treated with LDR interstitial brachytherapy
have an excellent long-term outcome. There was a small but statistically significant advantage in
bPFS and a trend toward improved CSS in patients with a primary Gleason pattern of 3.  2013
American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.Keywords: Prostate cancer; Gleason score 7; Brachytherapy; OutcomesIntroduction
Since its introduction, Gleason score has proven to be an
important prognosticator for treatment outcome in adeno-
carcinoma of the prostate (1, 2). This is evidenced by the
fact that nearly every prostate cancer risk stratification
system and nomogram includes Gleason score as a predic-
tive variable (3e5). There nevertheless remains a degree of
heterogeneity within each individual Gleason score subset.h 2012; received in revised form 11 May 2012;
2.
author. Schiffler Cancer Center, Wheeling Jesuit
Park, Wheeling, WV 26003. Tel.: þ1-304-243-
3-5047.
errick@urologicresearchinstitute.org (G.S. Merrick).
nt matter  2013 American Brachytherapy Society. Publis
.1016/j.brachy.2012.05.002This is particularly true among Gleason 7 cancers, where
some studies have shown a primary Gleason pattern 4 to
carry a higher risk of biochemical recurrence than a primary
pattern 3 (6, 7).
We previously published our experience with Gleason 7
prostate cancer patients treated with permanent interstitial
brachytherapy and found no statistically significant differ-
ences in biochemical progression-free survival (bPFS),
cause-specific survival (CSS), or overall survival (OS)
between the Gleason 3þ 4 and Gleason 4þ 3 subsets (8).
With a larger database of patients and longer median fol-
lowup, we now update our experience. To date, the present
study represents the largest published series of Gleason 7
prostate cancers treated with interstitial low-dose-rate
(LDR) brachytherapy.hed by Elsevier Inc. All rights reserved.
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Between April 1995 and June 2011, 932 consecutive
patients with Gleason score 7 (546 with primary Gleason
pattern 3 and 386 with primary Gleason pattern 4) prostate
cancer underwent permanent interstitial implant by a single
brachytherapist (GSM). The primary Gleason score (3 vs.
4) was assigned according to the predominant architectural
pattern (O50%) in the malignant component of the
submitted biopsy specimens. Biopsy slides were reviewed
by a single pathologist (EA) before formulating a treatment
plan. All patients underwent brachytherapy implant more
than 3 years before analysis.
Before performing the implant procedure, all patients were
clinically staged with medical history, physical examination,
and serum prostate-specific antigen (PSA). High-risk Gleason
7 patients (PSA O10 ng/mL and/or clinical stage $T2c)
underwent a radiographic workup including bone scan and
computed tomographyof the abdomen/pelvis. Seminal vesicle
biopsies and surgical lymph node stagingwere not performed.Table 1
Clinical, treatment, and dosimetric parameters, stratified by primary Gleason pa
Parameter
Gleason 3þ 4 (n5 546) Gleason
Median Mean SD Median
Age at implant (y) 66.2 65.7  7.4 67.3
Followup (y) 7.4 7.8  3.5 7.8
PSA 6.2 7.3  4.5 6.8
PPCs 34.2 41.5  24.3 50.0
Body mass index 27.4 28.0  4.7 28.0
Prostate volume 32.4 32.6  8.8 30.6
Planning volume 61.3 60.8  12.6 59.1
V100 98.1 96.8  4.4 98.2
V150 71.6 69.6  11.9 73.0
V200 41.3 40.2  10.5 42.6
D90 119.9 119.7  12.2 121.1
Most recent PSA !0.02 0.04  0.08 !0.02
Number of biopsy cores 8.0 12.3  12.9 8.0
Count n (%) Cou
Risk group
Intermediate 518 (94.9) 327
High 28 (5.1) 59
Clinical stage
T1beT2a 486 (89.0) 312
T2beT2c 58 (10.6) 71
T3 2 (0.4) 3
Isotope
125I 22 (4.0) 14
103Pd 523 (96.0) 372
XRT
No 175 (32.1) 93
Yes 371 (67.9) 293
ADT
None 416 (76.2) 241
!6 mo 95 (17.4) 72
O6 mo 35 (6.4) 73
SD5 standard deviation; PSA5 prostate-specific antigen; PPCs5 percenta
XRT5 external beam radiation therapy; ADT5 androgen deprivation therapy.
Bold indicates statistical significance.The brachytherapy target volume consisted of the pros-
tate gland and periprostatic region with a resultant planning
volume 1.75  the ultrasound-determined volume (9, 10).
Our preplanning technique and methods for Day 0 dosi-
metric evaluation have previously been described in detail
(9, 11). Calculation algorithms and seed parameters used
in preplanning and postoperative dosimetry were those rec-
ommended by the American Association of Physicists in
Medicine Task Group No. 43 (TG-43) (12). The minimum
peripheral dose (mPD) was prescribed to the target volume
with margin.
Of the 932 patients, 895 (96.1%) were implanted with
palladium-103 (103Pd) and 36 (3.9%) with iodine-125
(125I) (Table 1). Two hundred sixty-eight (28.7%) patients
were treated with brachytherapy implant alone. In this pop-
ulation of patients, the mPD was 125 Gy (National Institute
of Standards and Technologies 99) for 103Pd and 145 Gy
(TG-43) for 125I. The remainder of study patients (71.3%)
received supplemental external beam radiation therapyttern
4þ 3 (n5 386)
p
Total (n5 932)
Mean SD Median Mean SD
66.4  7.4 0.143 66.6 66.0  7.4
7.9  3.4 0.578 7.6 7.8  3.4
9.0  7.1 !0.001 6.4 8.0  5.8
47.1  25.1 !0.001 38.1 43.8  24.8
28.9  4.8 0.007 27.6 28.4  4.9
31.2  9.4 0.025 31.7 32.0  9.0
58.8  14.0 0.031 60.4 60.0  13.2
96.6  5.2 0.645 98.1 96.7  4.7
69.9  13.0 0.683 72.2 69.7  12.4
41.2  11.6 0.193 41.7 40.6  11.0
10.6  13.7 0.319 120.6 120.1  12.8
0.04  0.08 0.857 !0.02 0.04  0.08
11.1  11.2 0.131 8.0 11.8  12.2
nt n (%) p Count n (%)
(84.7) 845 (90.7)
(15.3) !0.001 87 (9.3)
(80.8) 798 (85.6)
(18.4) 129 (13.8)
(0.8) 0.002 5 (0.5)
(3.6) 36 (3.9)
(96.4) 0.749 895 (96.1)
(24.1) 268 (28.7)
(75.9) 0.008 665 (71.3)
(62.4) 657 (70.5)
(18.7) 167 (17.9)
(18.9) !0.001 108 (11.6)
ge of positive biopsy cores; 125I5 iodine-125; 103Pd5 palladium-103;
Fig. 1. Biochemical progression-free survival, stratified by primary Glea-
son pattern.
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XRT was delivered at two dose levels (20 and 44e50.4
Gy) using a three-dimensional conformal technique. The
planning target volume was inclusive of the prostate and
proximal seminal vesicles plus margin. In patients with
pelvic lymph node riskO10%, this volume was also inclu-
sive of the pelvic nodal basins extending superiorly to the
L5eS1 interspace (5). Among patients receiving XRT,
238 received 20 Gy and 427 received doses in the range
of 44e50.4 Gy. In this same group, 452 patients were
treated to the prostate only and 213 to the whole pelvis.
For patients receiving 44e50.4 Gy of XRT, the mPD was
90 Gy (National Institute of Standards and Technologies
99) for 103Pd and 110 Gy (TG-43) for 125I. In those
receiving 20 Gy of XRT, the boost was always delivered
using 103Pd with an mPD of 115 Gy.
Androgen deprivation therapy (ADT) was administered
for potential pubic arch interference or adverse disease
features. Two hundred seventy-five patients (29.5%)
received ADT. This included 167 patients (17.9%) receiving
6 months or less of a leutinizing hormoneereleasing
hormone agonist for prostate gland cytoreduction and 108
patients (11.6%) receiving O6 months of a leutinizing
hormoneereleasing hormone agonist and an oral antiandro-
gen for adverse pathologic features. In patients receiving
ADT, 25 received implant alone and 250 received implant
in conjunction with XRT.
After brachytherapy, patients were monitored by digital
rectal examination and serial PSA measurement at 6-month
intervals. The primary end points of this analysis were
bPFS, CSS, and OS. Biochemical control was defined as
a PSA #0.40 ng/mL after nadir (13). Patients dying with
either metastatic prostate cancer or castrate-resistant
disease in the absence of metastases were classified as
experiencing a prostate cancererelated death.
Continuous and categorical variables of interest were
compared using an independent t test and chi-squared
analysis, respectively. Comparisons in bPFS, CSS, and
OS between the two study cohorts were done using the
KaplaneMeier method. Univariate Cox regression analysis
was used to identify predictors of treatment outcome.
Those variables with p-value!0.10 were then entered into
a multivariate forward conditional Cox regression. Statis-
tical analysis was performed with SPSS v. 13.0 software
(SPSS Inc., Chicago, IL).Fig. 2. Cause-specific survival, stratified by primary Gleason pattern.Results
With a median followup of 7.4 years, the 10- and 14-year
bPFS, CSS, andOS for the entire Gleason 7 study groupwere
95.7/95.7%, 98.6/98.6%, and 77.2/64.3%, respectively.
Compared with primary Gleason pattern 3, the Gleason
pattern 4 patients had a statistically higher pretreatment
PSA and percentage of positive biopsy cores (PPCs)
(Table 1). The Gleason pattern 4 patients also receivedXRTmore frequently and had a higher incidence and average
duration of ADT use. When biochemical control was evalu-
ated as a function of primary Gleason pattern, the primary
pattern 3 had a statistically higher 10- and 14-year bPFS
(97.8/97.8% vs. 93.1/93.1%, p5 0.006) (Fig. 1). The Glea-
son pattern 3 patients also trended toward a higher 10- and
14-year CSS (99.3/99.3% vs. 96.9/96.9%, p5 0.058)
(Fig. 2). OS was not statistically different between the two
Gleason 7 cohorts (78.2/70.7% vs. 76.0/56.9%, p5 0.198)
(Fig. 3).
Subset analyses were performed to control for imbalances
in PSA and PPC between the two study groups. In the subset
of patientswith PSA#10, primaryGleason pattern 3 patients
maintained a significantly higher 10- and 14-year bPFS
(98.7/98.7% vs. 94.8/94.8%, p5 0.009) and CSS (100/
100% vs. 97.0/97.0%, p5 0.013). In those patients with
PSAO10, the bPFS (93.0/93.0% vs. 90.0/90.0%, p5 0.52)
Fig. 3. Overall survival, stratified by primary Gleason pattern.
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according to primary Gleason pattern. In the subset of
patients with PPC#50%, there was a trend toward improved
bPFS (97.5/97.5% vs. 94.3/94.3%, p5 0.14) and CSS (99.8/
99.8% vs. 97.5/97.5%, p5 0.066) for Gleason pattern 3, but
this did not reach statistical significance. In those patientsTable 2
Predictors of bPFS, OS, and CSS on univariate/multivariate analysis
Variables
bPFS O
Univariate Multivariate U
p RR p RR p
Gleason score: 3 þ 4 vs. 4 þ 3 0.005 2.726 0.024 2.265
Age 0.051 0.298 !
PSA !0.001 1.057 0.018 1.042
% Positive biopsies 0.018 1.015 0.510
Body mass index 0.616
Prostate volume 0.006 1.046 0.002 1.053
%D90 0.285
Perineural invasion 0.825
Stage !0.001 !0.001
T1beT2a vs. T2beT2c !0.001 5.519 !0.001 4.319
T1beT2a vs. T3aeT3c 0.042 8.079 0.070
Isotope 0.593
Risk (intermediate vs. high) !0.001 4.477 0.488
XRT 0.078 0.507
ADT 0.339
ADT duration 0.175
Hypertension 0.137
Diabetes 0.769
Tobacco use 0.087 0.053 !
Never vs. former
Never vs. current !
Coronary artery disease 0.184
Hypercholesterolemia 0.015 0.307 0.041 0.371
bPFS5 biochemical progression-free survival; OS5 overall survival; CS
antigen; XRT5 external beam radiation therapy; ADT5 androgen deprivation t
Bold indicates statistical significance.with PPCO50%, there was a superior bPFS among primary
Gleason pattern 3 patients (97.7/97.7% vs. 90.5/90.5%,
p5 0.018), but this did not translate into an improved CSS
(97.9/97.9% vs. 96.4/96.4%, p5 0.69).
Univariate and multivariate analyses were performed to
identify the strongest predictors of bPFS, CSS, and OS
(Table 2). Primary Gleason pattern was predictive of bPFS
on both univariate (relative risk, 2.73; p5 0.005) and multi-
variate (relative risk, 2.265; p5 0.024) analyses. Primary
Gleason pattern also trended toward predicting CSS
( p5 0.081) on univariate analysis although this did not
reach statistical significance.Discussion
Gleason score is an important prognostic factor having
been shown to predict for bPFS and CSS after definitive
treatment of prostate cancer (1e5). Gleason 7 prostate
cancer represents one of the most common histologic
patterns. Some studies indicate that within the Gleason 7
stratum, a primary pattern 4 carries a less favorable prog-
nosis than a primary pattern 3, although conflicting results
have been reported (5e8, 14e17).
In a prior publication, we reported our outcome data
for Gleason 7 patients treated with LDR interstitial bra-
chytherapy. At that time, there were no statisticallyS CSS
nivariate Multivariate Univariate Multivariate
RR p RR p RR p RR
0.199 0.081
0.001 1.114 !0.001 1.122 0.384
0.761 0.110
0.980 0.470
0.139 0.296
0.395 0.179
0.885 0.178
0.249 0.796
0.891 0.122
0.503 0.633
0.916 0.055
0.591 0.361
0.608 0.657
0.948 0.415
0.289 0.205
0.002 1.890 0.011 1.683 0.828
0.001 !0.001 0.624
0.214 0.525
0.001 2.199 !0.001 2.782
0.001 1.822 0.045 1.435 0.444
0.755 0.344
S5 cause-specific survival; RR5 relative risk; PSA5 prostate-specific
herapy.
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pattern 3 and 4 (8). In this updated analysis, which
includes a larger study population and longer median fol-
lowup, we are now seeing a trend in outcome that favors
primary Gleason pattern 3. The primary Gleason 3 cohort
exhibited a superior bPFS and a nonsignificant trend
toward improved CSS.
One notable limitation of the present study is an imbal-
ance in prognostic factors between the two study arms. The
primary Gleason 4 population had a statistically higher
PSA and PPC, which in itself would portend a less favor-
able outcome. In an attempt to adjust for the confounding
effect of PSA and disease volume, we conducted subgroup
analyses. Primary pattern 3 patients continued to exhibit
superior bPFS in the subset of patients with either PSA
#10 or PPCO50%. Statistical significance was not main-
tained among patients with PSAO10 or PPC #50%. This
likely relates to a loss of statistical power within these
subsets, but the possibility of an unexpected relationship
between PSA/PPC and primary Gleason pattern cannot be
excluded.
Overall, this Gleason 7 patient population treated with
LDR interstitial brachytherapy did exceptionally well. Even
among primary pattern 4 patients, long-term CSS was
96.9% and bPFS was 93.1%. These results compare favor-
ably with published prostatectomy data, where bPFS rates
in the range of 38e48% have been reported in patients with
comparable disease features (15). This marked difference in
biochemical outcome between the two treatment modalities
may be because of the inability of prostatectomy to effec-
tively eradicate subclinical extracapsular disease. Although
the difference in bPFS between primary Gleason 3 and 4
was statistically significant in this study, the magnitude of
this difference was relatively small. It is unlikely that
further intensification of local therapy would have miti-
gated the differences in outcome between the primary Glea-
son 3 and 4 given the relatively high biologic doses that
were used in this study (18). A slightly higher incidence
of subclinical metastatic disease among primary Gleason
4 patients may provide an explanation for the observed
differences.Conclusions
Gleason 7 prostate cancer patients treated with LDR
interstitial brachytherapy have an excellent long-term
outcome. There was a small but statistically significant
advantage in bPFS and a trend toward improved CSS in
patients with a primary Gleason pattern of 3.References
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